The Mastocytosis Society, Inc. (TMS) 2020 Patient Survey to Assess Impact of COVID-19 in Patients with Mast Cell Disease
This survey will remain open for the foreseeable future
You are invited to participate in a survey being conducted by Middle Tennessee State University (MTSU) researchers, in collaboration with The Mastocytosis Society, Inc. (TMS), designed to assess the impact of COVID-19 in patients with Mast Cell Disease. Data obtained from this survey will be used for discussion, investigation, presentation, and publications in medical journ ls to share knowledge gained about managing patients affected by both COVID-19 and pre-existing Mast Cell Disease. This survey is expected to take approximately 25 minutes to complete.
Adult patients and caregivers of adult and pediatric patients under age 18 who have been diagnosed with Mast Cell Disease, including Mastocytosis, Mast Cell Activation Syndrome (MCAS), and Hereditary Alpha Tryptasemia (HaT), by any physician or clinic, may take this survey if they have had any possible exposure to COVID-19, or have had symptoms of COVID-19, regardless of COVID-19 test results or COVID-19 diagnosis.
If in doubt, take the survey.
If you would like to participate in this survey,
please click here.
If your experience with COVID-19 changes after taking the survey, you may retake the survey. Please visit the TMS 2020 COVID-19 Survey webpage for important instructions on how to retake the survey.
TMS appreciates the collaborative effort and expertise of members of the TMS Medical Advisory Board/Mast Cell Disease specialists, as well as scientists from Middle Tennessee State University, in the development of this survey.
For any questions, please contact: research@tmsforacure.org.
TMS 2020 Mast Cell Disease COVID-19 Survey Team
The Mastocytosis Society, Inc.
www.tmsforacure.org
Text Box
Arts and Entertainment
Business and Industry
Computer and Electronics
Games
Health
Internet and Telecom
Shopping
Sports
Travel
More